Derbyshire Lab Finds Hsp90 Inhibitors That May Aid in Treating Malaria

The collaborative efforts of the Derbyshire and Haystead labs reveal that compounds that bind to Hsp90 represent a class of molecules that inhibit both blood- and liver-stage Plasmodium parasites. This dual-stage inhibition is ideal for antimalarials, and their work highlights the potential of Hsp90 inhibitors as drug partners in combination therapies.  Read more about this research in an April issue of Antimicrobial Agents and Chemotherapy article here.